(IN BRIEF) Researchers at the Karlsruhe Institute of Technology (KIT) have created a nanodroplet-based chip platform that combines drug synthesis, biological testing, and chemical analysis in a single workflow. Each droplet measures only 200 nanoliters and contains 300 cells, enabling … Read the full press release
Posted in Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged Angewandte Chemie, biotechnology, cancer research, Carsten Hopf, CeMOS, colon cancer, direct-to-biology, drug discovery, HT-29, Karlsruhe Institute of Technology, KIT, Liana Bauer, MALDI-MSI, MEK inhibitors, miniaturized workflow, mirdametinib, nanodroplet array platform, Pavel Levkin, pharmaceuticals, skin cancer, TH Mannheim
(IN BRIEF) The University of Glasgow is leading the innovative FOxTROT 5 trial, which is offering elderly colon cancer patients the opportunity to participate in a groundbreaking immunotherapy study. The trial will administer dostarlimab before surgery, targeting a specific type … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged cancer research, cancer treatment, chemotherapy, clinical trial, clinical trial protocol, colon cancer, deficient mismatch repair, dMMR, dostarlimab, Elderly Patients, FOxTROT 5, frail patients, GSK, immunotherapy, partnership, precision oncology, surgery, UK hospitals, University of Birmingham, University of Glasgow, University of Leeds
(IN BRIEF) Researchers from the University of Copenhagen and Rigshospitalet have made significant strides in developing a new treatment for pancreatic cancer using antibody-drug conjugates (ADCs). This targeted therapy promises to improve survival rates by precisely attacking cancer cells while … Read the full press release
Posted in Business, Denmark, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology
Tagged ADC, antibody-drug conjugates, cancer treatment, chemotherapy, colon cancer, Finsen Laboratory, human clinical trials, immune system, Lars Henning Engelholm, pancreatic cancer, pharmaceutical research, precision medicine, Rigshospitalet, sarcoma, Science Advances, survival rates, targeted therapy, triple-negative breast cancer, University of Copenhagen
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?